AMBASSADOR: Adjuvant Pembro Boosts DFS in Urothelial Cancer
Interim findings from the ongoing AMBASSADOR trial revealed a significant DFS benefit with adjuvant pembrolizumab but no overall survival benefit at this point.
Source: medscape.com
Bladder Cancer Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Bladder Cancer Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Bladder Cancer Program Today - Breaking & Trending Today
Cancer Conundrum: Immune Checkpoint Inhibitor Use in Transplant Recipients
Randomized clinical trials of ICIs have traditionally excluded immunocompromised individuals, but emerging evidence suggests the drugs have the potential to treat advanced cancers in transplant recipients. Clinicians face a challenge in the use of immune checkpoint inhibitor therapy in organ transplant recipients because of their need for immunosuppression.
Source: renalandurologynews.com
UroGen Pharma - New Retrospective Study Presented at AUA 2023 Provides Evidence of Similar Outcomes Utilizing JELMYTO in the Treatment of UTUC of the Ureter and Renal Pelvis
PRINCTON - UroGen Pharma Ltd. , a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today highlights the results of a... | May 1, 2023
Source: marketscreener.com
New Retrospective Study Presented at AUA 2023 Provides Evidence of Similar Outcomes Utilizing JELMYTO® in the Treatment of UTUC of the Ureter and Renal Pelvis
UroGen Pharma Ltd. , a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today highlights the results of a sub-analysis... | April 30, 2023
Source: marketscreener.com